Key Highlights

  • Auna S.A. (NYSE:AUNA) shares closed 12.37% lower, a decline of about 12.4%, on November 18, 2026, the session after third-quarter results.
  • Revenue rose 10% on a currency-neutral basis to PEN 1.33 billion, but adjusted EBITDA fell 4.6% to PEN 231 million and the Margin slipped to 17.5%.
  • The company now expects full-year adjusted EBITDA to be broadly stable or slightly down, as Colombia's segment EBITDA fell 30%.
  • Auna terminated an unprofitable oncology risk-sharing contract in Colombia, while Leverage improved to 3.5 times.

Revenue Growth, Margin Pressure

Auna operates hospitals, clinics and oncology-focused health plans in Peru, Mexico and Colombia. Its third-quarter report, released after the close on November 17, showed healthy Demand but rising cost pressure. Consolidated Revenue reached PEN 1,325 million, up 10% on a currency-neutral basis and 19% as reported. Local currency revenue rose 16% in Mexico, 12% in Colombia and 6% in Peru. Surgeries increased 12% and hospital days 6%, which points to steady patient volumes. Profitability moved the other way. Adjusted EBITDA fell 4.6% on a currency-neutral basis to PEN 231 million, flat as reported, and the margin declined to 17.5% from 18.4% in the second quarter. By segment, Mexico grew EBITDA 5%, its first year-on-year increase in 2026, while Peru fell 6% because of penalties from reconciling prior years' receivables, higher medical loss ratios and new oncology plans. Colombia was the main drag, with segment EBITDA down 30% on adverse costs under one oncology risk-sharing contract, regulatory price caps on high-cost cancer drugs and higher personnel costs.

Guidance Reset and the Colombia Contract

The guidance change was the main cause of the share price fall. The company reaffirmed currency-neutral revenue growth of 10% to 14% for 2026 but now expects adjusted EBITDA to be broadly stable or slightly down year on year. Earlier in the year, management had targeted double-digit EBITDA growth, and a reset at an investor event in October had already cut the shares by about 16% in early trading. This second step down suggests the pressure in Colombia and Peru has not yet stabilized. Auna has terminated the Colombian oncology risk-sharing contract that caused much of the damage. The arrangement represented about 4% of Colombia's revenue, and the company has engaged legal counsel to review Options for recovering losses. Ending the contract should remove a source of unpredictable costs, but it also reduces revenue, and the drug price caps imposed by Colombian regulators remain in place. Net Income fell to PEN 24 million from PEN 53 million, mainly because the prior-year quarter benefited from a PEN 40 million non-cash currency gain, and net finance costs rose to PEN 112 million from PEN 72 million.

Cash Flow, Leverage and Outlook

The Balance Sheet trend was more encouraging. Year-to-date operating Cash Flow rose 62% to PEN 713 million, and free cash flow rose 95% to PEN 626 million, which helped bring the Leverage Ratio down to 3.5 times EBITDA. Management's medium-term target is below 3.0 times, and Capital spending is planned at about 4% of revenue. Strong cash generation gives the company room to reduce Debt even with flat EBITDA, but high interest costs continue to absorb much of the operating profit. The stock had already fallen sharply this year before the latest drop, so the valuation now reflects considerable pessimism. For investors, the key questions are whether Colombian margins can recover once the contract ends, whether Peru's one-off penalties fade and whether Mexico, the fastest-growing market, can carry consolidated growth. Emerging market currency weakness adds another risk, as the dollar strengthened on November 18 and Latin American currencies fell. A construction start on a new ambulatory center in Lima shows that expansion continues, although at a measured pace.

Where Things Stand

Auna fell 12.4% on November 18 after cutting its 2026 EBITDA outlook to broadly stable or slightly down, as a loss-making oncology contract and drug price caps hit Colombia. Revenue growth and cash flow remain solid and leverage is falling, but investors want evidence that margins have stabilized before rerating the shares.